Navigation Links
Therapure Biopharma Inc. Announces Delivery of its First Commercial-Scale Lyophilizer
Date:11/8/2009

Freeze-drying of biopharmaceuticals to be available at the Company’s Mississauga, Ontario facility.

Toronto, ON (PRWEB) November 8, 2009 -- Thomas Wellner, President and CEO of Therapure Biopharma Inc. today announced that the Company has taken delivery of a commercial scale pharmaceutical grade freeze dryer and expects to make commercial scale freeze drying (lyophilization) available for contract manufacturing of biopharmaceuticals early in 2010.

Lyophilization is used to convert biopharmaceuticals that are manufactured in an unstable liquid format into a stable, dry powder that can be reconstituted to a liquid format for administration to patients. Lyophilized forms of these life-saving products are more easily handled and stable than their liquid forms and therefore lyophilization is commonly used in the manufacture of these products.

“Commercial scale lyophilization is not readily available in Canada,” said Thomas Wellner. “The addition of a commercial-scale lyophilizer to the clinical scale capability Therapure Biopharma has now will significantly enhance the value we will bring to Therapure clients.”

Installation of the lyophilizer began last week and is expected to be completed in December. Following the installation, the Company will complete the extensive validation process required to achieve current Good Manufacturing Practices (cGMP) status. Therapure Biopharma will begin offering commercial-scale lyophilization services from its Health Canada commercially licensed plant early in 2010.

About Therapure Biopharma:
Therapure Biopharma Inc. is an integrated biopharmaceutical company that develops, manufactures, purifies, and packages therapeutic proteins. As a contract development and manufacturing organization (CDMO) Therapure Biopharma applies scientific, manufacturing, and downstream purification expertise with an i
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Therapure Biopharma Inc. and LFB Biotechnologies Announce Development Services Contract for New Therapeutic Protein
2. Surviving Healthcare Reform: How Biopharma Companies Can Come Out on Top
3. aTyr Pharma to Present at Japan Biopharma Partnering Conference
4. Keryx Biopharmaceuticals, Inc. to Hold Investor/Analyst Day Tomorrow
5. DOR BioPharma Announces $9.4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines
6. PDL BioPharma Announces Conversion Rate Adjustment for Its 2.75% Convertible Subordinated Notes Due August 16, 2023
7. Keryx Biopharmaceuticals Receives Orphan-Drug Designation for KRX-0401 (Perifosine) for the Treatment of Multiple Myeloma
8. UK's Newcastle University Introduces First-Ever Biopharmaceutical Engineering Doctorate Program
9. PDL BioPharma to Present at BioCentury Newsmakers Conference on September 16, 2009
10. Frost & Sullivan Global Heart Health Ingredients Excellence in Financial & Risk Management Award Conferred on Pronova BioPharma
11. Keryx Biopharmaceuticals, Inc. To Present at the Rodman & Renshaw Annual Global Investment Conference and To Hold Investor/Analyst Day

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...survivors of testicular cancer who were treated wi...de effects, including neurological side effects an...eated with chemotherapy, according to a new study ...e National Cancer Institute . , Marianne Brydy, ...versity Hospital, in Bergen, Norway, and colleague...
(Date:11/25/2009)...lready used to fight rheumatoid arthritis, could h... , WEDNESDAY, Nov. 25 (HealthDay News) -- A dr...nd rheumatoid arthritis now also shows some promis...diabetes. , The drug, rituximab (Rituxan), help...in, even though the disease had destroyed some of ...
(Date:11/25/2009)...ORK,Nov.25/PRNewswire/-- MISSIONSkincare ®isp...orSt.Jude.AspartofGNC,sannualSt.Jude ThanksandGivi...kincare,s new SUPER-C(TM)LipBalm willbedonatedto...ytomakea$1,$5or$10donationatcheckoutatoneoftheir5,...than$1millionforSt.Judeduringtheir2009 ThanksandGi...
(Date:11/25/2009)...s behavior problems that can occur in children wit...h a treatment plan that includes medication combin... according to Yale University researchers and thei...issue of the Journal of the American Academy of C...ducted by the National Institute of Mental Health ...
(Date:11/25/2009)... BioSpace.com, the premier resource f...the third edition of the BioForest™ Hotbed C...nglewood, CO (Vocus) November 25, 2009 -- BioSpace...s and information, unveiled the third edition of t... , , , ,This regional campaign is a promotional e...
Breaking Medicine News(10 mins):Health News:Type 1 Diabetes May Have a New Foe 2Health News:Type 1 Diabetes May Have a New Foe 3Health News:MISSION Skincare(R) Supports GNC's Efforts To Raise Money for St. Jude Children's Research Hospital(R) 2Health News:Parent training key to improved treatment of behavior problems in children with autism 2Health News:BioSpace Showcases Leading Life-Science Companies in the Northwest 2
...ull House and,Senate poised to vote on the Preside...horization bill, a five-year, $50 billion initiati...rldwide, Congress must address,the critical HIV pr... nearly two million more,people have access to ant...
...LY AGGRESSIVE VACCINATION SCHEDULE TO,COMBAT RISIN...children who,regressed into autism after receiving...vernment health officials may at last be catching ...nference call held earlier in March,bringing toget...
...tinue the habit after initial coil treatment surge...- Smokers with a brain aneurysm who are treated wi...tients to develop another aneurysm, according to a...the groin and then threaded to the affected area o...
...w medications longer, study finds , , FRID...second-generation antipsychotics are no better tha...pisode of schizophrenia, a new study finds. , Howe... we compared newer drugs to older drugs, we found ...
... T. Clark, Chief,Executive Officer and President o...eutical Research and Manufacturers of America (PhR...g. Also elected were AstraZeneca Chief,Executive O...asurer., In addition, PhRMA announced that Takeda...
...n German . , Boxing is possibly less dangerous ... amateurs. However, conclusive statements on the l...ssional boxers such as Muhammad Ali contracted the...il more extensive studies of both amateur and prof...
Other Medicine News:Health News:Will Congress Do More for HIV Prevention? 2Health News:Will Congress Do More for HIV Prevention? 3Health News:Will Congress Do More for HIV Prevention? 4Health News:MITOCHONDRIAL DYSFUNCTION, VACCINES AND AUTISM: 1 in 50 Children Could Be at Risk 2Health News:Smokers at Increased Risk of Aneurysm Recurrence 2Health News:New Drugs No Better Than Older Ones for Schizophrenia 2Health News:New Drugs No Better Than Older Ones for Schizophrenia 3Health News:Richard T. Clark Elected PhRMA Board Chairman 2Health News:Richard T. Clark Elected PhRMA Board Chairman 3Health News:Richard T. Clark Elected PhRMA Board Chairman 4Health News:Richard T. Clark Elected PhRMA Board Chairman 5Health News:How dangerous is boxing for the brain? 2
(Date:11/24/2009)...,, IRVINE,Calif.,Nov.24/PRNewswire-FirstCall...llyinvasivetreatmentsforaorticdisorders,announcedt...oceedingsin,thepatentinfringementlawsuitbroughtaga...heUnitedStatesDistrictCourtinIndianapolis,Indiana....ectwhiletheUnitedStatesPatentandTrademarkOffice(US...
(Date:11/24/2009)...,, WOODCLIFFLAKE,N.J.andNEWYORK,Nov.24/PRNew...heU.S.FoodandDrugAdministration(FDA)hasacceptedfor...mgAricept®(donepezilHClextendedrelease)tablet...se(AD).Thisnewhigherdoseformulationcontains23mgofd...thadeliverysystemthatallowsforgradualreleaseofthed...
(Date:11/24/2009)...,, STAMFORD,Conn.,Nov.24/PRNewswire/--Zargis...E )andaspin-offfromSiemensCorporateResearch(NYSE: ...sfeaturedontheNovember24,2009episodeofCBS, TheEarl...PopularScience magazine,reviewedfivewinningproduct...,, TheEarlyShow isawidely-viewedtelevisionmorn...
Breaking Medicine Technology:Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement 2FDA Accepts Once Daily 23 mg Aricept(R) Extended Release NDA for Review 2FDA Accepts Once Daily 23 mg Aricept(R) Extended Release NDA for Review 3Zargis Cardioscan(TM) Featured on The Early Show on CBS 2Zargis Cardioscan(TM) Featured on The Early Show on CBS 3Arcadia Resources Announces Webcast of its Fiscal 2009 Fourth Quarter and Year End Conference Call 48847 1Arcadia Resources Announces Webcast of its Fiscal 2009 Fourth Quarter and Year End Conference Call 48847 2Forterus Inc Treatment Centers Serving Middle Class 3B Rapid Growth Detailed in Paul Howarth Interview 48844 1Forterus Inc Treatment Centers Serving Middle Class 3B Rapid Growth Detailed in Paul Howarth Interview 48844 2Parents In Wisconsin Can Now Test Their Children For Lead Exposure Using Saliva 48843 1Parents In Wisconsin Can Now Test Their Children For Lead Exposure Using Saliva 48843 2Parents In Wisconsin Can Now Test Their Children For Lead Exposure Using Saliva 48843 3Parents In Wisconsin Can Now Test Their Children For Lead Exposure Using Saliva 48843 4
...INESS WIRE)--Apr 16, 2007 - Amgen,(Nasdaq:AMGN) to...e-blind, placebo-controlled Phase 3 study evaluati...tin alfa) for the,treatment of anemia in patients ...adiotherapy ("the 103 study"). Aranesp is not,appr... These,results were presented in an oral session a...
...primary endpoint not met; plausibly,confounded by ...TUX,-, NEW YORK, April 16, 2007 /PRNewswire-FirstC...yers Squibb Company today,announced detailed resul... multi-center Phase III trial - comparing ERBITUX(... in patients with,metastatic colorectal cancer (mC...
Other Medicine Technology:Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 2Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 3Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 4Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 5Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 6Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 7Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 2Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 3Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 4Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 5Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 6Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 7Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 8Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 9
Sophia Vest V-654
Gabrielle Vest V-650
Female Mini-VEST, Front Closure, X-Firm
Male Support Brief
Medicine Products: